Under the terms of the agreement following the final review of quantities by each European Union (EU) Member State, Valneva plans to deliver 24.3 million doses in the second and third quarters of 2022, subject to the approval of VLA2001 by the European Medicines Agency (EMA). The Commission has the possibility to increase this first binding order to a total of 60 million doses, the rest of which would be delivered in 2023. COVAX is the vaccine pillar of the COVID-19 Tools Access Accelerator (ACT), a groundbreaking global collaboration to accelerate the development, production and equal access to COVID-19 tests, treatments and vaccines. COVAX is jointly led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO. Most donations are for less than 1 million doses and the cans cover only a small part of the beneficiary`s population. So far, the majority of doses promised or delivered are administered to low- and middle-income countries (355.7 million, including three donations totalling 27 million doses to the African Union), followed by 142.8 million to middle-income countries and 65.6 million to low-income countries. An additional 17.8 million doses are for high-income countries. Overall, low-income countries received relatively few donations – both in terms of total doses given and the proportion of these donations in the total population. Among current grants, most beneficiaries in low-income countries have a population coverage of 5% or less. Where price information is available, there are significant differences in prices both within and between vaccine candidates. Questions were raised about the fairness of these variations.

For example, AstraZeneca`s vaccine is more expensive in Uganda ($7) and South Africa ($5.25) than in the European Union ($3.50). Similarly, there have been conflicting reports that Brazil would pay about $10 per dose for Sinovac, while Ukraine paid about $18 per dose. While efforts are made to ensure the accuracy and completeness of the data, the data may be incomplete or outdated due to the lack of detailed information available to the public and the expeditious nature of these agreements. So far, however, only some of these commitments have been implemented. For example, the US and the EU delivered less than a quarter of the total doses promised, according to the IMF on December 6, 2021. In addition, almost 15% of secondary agreements lack public information on at least one of the most important details, namely: h. Recipients, allocated doses or vaccines to be given. Of those who started sharing doses, some did so directly with recipients, while others shared through intermediaries such as COVAX or the European Union. Not all primary agreements are made public in a timely manner.

Those that are reported often lack basic information such as the total number of vaccines provided and their prices. The associated conditions (e.B delivery times, liability agreements, flexibility in resale) are also often unavailable. This lack of transparency makes it difficult to draw firm conclusions about global access to COVID-19 vaccines. Thomas Lingelbach, Chairman and CEO of Valneva, said: “We are delighted that the European Commission and the Member States have concluded this purchase agreement and are committed to helping to address the ongoing pandemic. We continue to receive messages from people around the world requesting access to an inactivated vaccine. Our Phase 3 results confirmed the benefits often associated with inactivated vaccines, and we continue to believe that our differentiated vaccine candidate can make an important contribution to the global fight against the COVID-19 pandemic. Last week, a newcomer to Johnson & Johnson was approved in the U.S. when Canada announced approval for AstraZeneca`s COVID-19 vaccine. Franck Grimaud, Chief Business Officer of Valneva, commented: “I would like to thank the EU teams and THE EU Member States who placed VLA2001 orders. We look forward to launching the ongoing review with the EMA after the appointment of the rapporteurs.

The recent wave of COVID-19 in Europe highlights the need for an alternative vaccine, and we have a ready-to-use vaccine inventory upon receipt of EMA approval. The confirmation of the EC agreement will also allow us to optimize our manufacturing strategy for VLA2001. These estimates show how COVID-19 vaccine prices differ from brand to brand and country to country. However, final price levels can sometimes differ significantly from those expected, as shown by recent discoveries related to Russia`s Sputnik V – originally touted as a cheap alternative to Western vaccines – suggesting that the vaccine is actually more expensive than competitors with similar efficacy. The data is updated once a month. Information on agreements is aggregated from publicly available sources, including news stories (links available in the dataset). Starting in September 2021, data collection on vaccine purchases and donations will also use the Twitter API. Details about the methodology and code can be found in the files downloadable with our dataset. Among donors, the U.S. is poised to become the largest donor after announcing it would buy and donate 500 million doses of Pfizer/BioNTech, in addition to previous announcements to share about 510 million doses. The European Union and its Member States have also committed to sharing more than 500 million doses.

Individually, the second largest donors are China and the United Kingdom, which have pledged about 100 million doses. Other major donors include Australia, Japan and Canada, which have each pledged to donate at least more than 50 million doses each. Purchase agreements with 119 countries or territories, the African Union, the European Union and COVAX have been publicly announced. [2] This includes vaccines that have not yet been approved. Many countries have also included in their treaties provisions to purchase additional doses at a later date; these optional doses are not included in the amounts shown here. In addition, it is important to note that these calculations do not include donations of vaccine doses between countries or doses expected by COVAX. As of December 8, 2021, eighty-four vaccines are in the late phase (phase 2 or 3) and thirty-three others in the post-registration phase. We found publicly declared purchase contracts for twenty-eight of them. In total, more than 16 billion doses of these vaccines have been reserved through agreements. Moderna`s COVID-19 vaccine was added to the Emergency Use List (EUL) by WHO on 30 April. On May 3, the COVAX facility announced that it had signed an initial purchase agreement to secure access to 34 million doses of Moderna`s COVID-19 vaccines in the fourth quarter of 2021 and up to 466 million doses in 2022.

VLA2001 is currently the only adjuvant vaccine candidate inactivated against COVID-19 in clinical trials in Europe. It is intended for active immunization of at-risk populations to prevent promotion and symptomatic infection with COVID-19 during the ongoing pandemic and possibly later for routine vaccination, including treatment of new variants. VLA2001 may also be suitable for the increase, as repeated booster injections have been shown to work well with inactivated vaccines of the entire virus. VLA2001 is produced on Valneva`s established Vero cellular platform and uses Valneva`s licensed IXIARO® Japanese encephalitis vaccine manufacturing technology. VLA2001 consists of whole inactivated sarS-CoV-2 virus particles with high density of S proteins, in combination with two excipients, alum and CpG 1018. . .